Brazil Healthcare Market Report 2026: ANVISA, SUS, CONITEC, and Pharmaceutical Market Intelligence

The Brazilian healthcare market is estimated at USD 155–175 billion in 2026, making it the largest healthcare market in Latin America and among the top 10 globally. Brazil operates a universal public healthcare system — SUS (Sistema Único de Saúde) — which provides constitutionally guaranteed healthcare to all 215+ million citizens, funded by federal, state, and municipal governments. Supplementary private health insurance (saúde suplementar), regulated by ANS (Agência Nacional de Saúde Suplementar), covers approximately 50 million Brazilians and accounts for approximately 35% of total healthcare spend. Brazil's pharmaceutical and device market is heavily influenced by both SUS procurement policies and the high-value private supplementary sector.

The Brazilian pharmaceutical market is estimated at USD 26–30 billion in 2026 — the largest in Latin America. ANVISA (Agência Nacional de Vigilância Sanitária) is Brazil's pharmaceutical regulatory agency, responsible for new drug registration, generic bioequivalence, and price regulation. CMED (Câmara de Regulação do Mercado de Medicamentos) sets maximum pharmaceutical prices in Brazil using the PCFAR (Preço Fábrica) and Preço Máximo ao Consumidor (PMC) framework. CONITEC (Comissão Nacional de Incorporação de Tecnologias no SUS) conducts HTA for SUS incorporation decisions. Brazil has over 220 domestic pharmaceutical manufacturers and a substantial generics and biosimilars industry.

ANVISA registration is required before any pharmaceutical product can be marketed in Brazil. Priority review tracks (PRE — Pedido de Análise Prioritária) are available for unmet medical need products. Standard review timelines range from 12–36 months depending on complexity. Following ANVISA approval, manufacturers seeking SUS reimbursement must apply to CONITEC for technology assessment. CONITEC evaluates clinical effectiveness, cost-effectiveness (cost/QALY or cost/LYG), and budget impact against the SUS perspective. The PCDT (Protocolo Clínico e Diretrizes Terapêuticas) framework defines treatment protocols and patient eligibility criteria for reimbursed medicines within SUS. Brazil's reference pricing framework references international prices from specific reference countries including the US, Canada, Australia, and EU5.

The five largest therapy areas in the Brazilian pharmaceutical market by combined public and private sector value are: oncology (rapidly growing; SUS has expanded cancer treatment coverage through RENAME and hospital protocols at INCA-affiliated cancer centres); diabetes (Brazil has the world's sixth-largest diabetic population; insulin, GLP-1 agonists, SGLT-2 inhibitors growing); cardiovascular (high volume: antihypertensives, statins, anticoagulants — generic-dominant); infectious diseases (HIV/AIDS treatment is fully funded by SUS — Brazil is globally recognised for its ARV access program); and immunology and biologics (TNF inhibitors, IL-17 inhibitors, JAK inhibitors growing in the private supplementary market with biosimilar adoption accelerating).

Brazil's ANS-regulated private supplementary health insurance sector covers approximately 50 million Brazilians and generates disproportionately high pharmaceutical and device revenues relative to its population share. ANS mandates a Rol de Procedimentos (minimum coverage list) that private insurers must cover, including specified medicines and medical procedures. The Rol was expanded in 2022 to include additional oncology therapies, biologics, and gene therapies. Premium private hospitals (Hospital Albert Einstein, Hospital Sírio-Libanês, Hospital BP, Hospital Mater Dei) are Brazil's most commercially attractive accounts for innovative branded pharmaceuticals and novel medical devices, operating at full international price points with limited price regulation compared to the SUS channel.

BioNixus delivers pharmaceutical and healthcare market research in Brazil: regulator-aware access intelligence, hospital consumption analogues, physician and payer qualitative programmes, and launch evidence under EphMRA and BHBIA governance with GDPR-aligned fieldwork for multinational sponsors. Teams receive decision-ready outputs validated against national policy and institution-level adoption—not desk extrapolation from unrelated regions.

BioNixus supports Brazil-based pharmaceutical companies expanding into GCC and MENA markets with SFDA and MOHAP regulatory intelligence, NUPCO and hospital procurement tracking in Saudi Arabia, UAE insurer and formulary research, physician panels across GCC countries, and comparative Brazil versus GCC market intelligence. GCC expansion is a distinct service line with its own tender and access calendars—see our GCC pharmaceutical market report for regional context. Launch assumptions should be validated market by market rather than from a single Gulf average.